Dong Zhou, Jie Yang, Wei-Dong Huang, Jun Wang, Qiang Zhang, Department of General Surgery, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang 441000, Hubei Province, China.
World J Gastroenterol. 2013 Nov 28;19(44):8108-13. doi: 10.3748/wjg.v19.i44.8108.
To determine the effects of RNAi-mediated inhibition of the growth hormone receptor (GHR) gene on tumors and colon cancer cells in vivo.
Construction of a eukaryotic vector for human GHR expression, the pcDNA6.2-GW/EmGFP-small interfering RNAs (siRNAs)-GHR plasmid, was used to inhibit GHR expression. Thirty-six BALB/c nude mice were randomly divided into groups and treated with normal saline (NS), recombinant plasmid (G₂), growth hormone (GH), 5-fluorouracil (FU), G₂+FU or G₂+FU+GH. Each nude mouse was subcutaneously inoculated with 1 × 10(7) human colon cancer SW480 cells; the nude mice were weighed before inoculation and on the 2(nd), 5(th), 8(th), 11(th), 14(th) and 17(th) day after inoculation. All nude mice were sacrificed after 17 d. Each subcutaneous tumor was removed and studied. Tumor volume was measured on the 5(th), 8(th), 11(th), 14(th) and 17(th) day after inoculation. The expression of GHR protein in the tumor tissue was detected by Western blotting analysis, and the differences in GHR mRNA expression in the tumor tissue were detected by real-time quantitative reverse transcription-polymerase chain reaction.
Compared to the control group, the weights of the inoculated nude mice on the 17(th) day after inoculation were: G₂: 21.60 ± 0.71 g, GH: 21.64 ± 0.45 g, FU: 18.94 ± 0.47 g, FU+G₂: 19.40 ± 0.60 g, G₂+FU+GH: 21.04 ± 0.78 g vs NS: 20.68 ± 0.66 g, P < 0.05; the tumor volumes after the subcutaneous inoculation were: G₂: 9.71 ± 3.82 mm(3), FU: 11.54 ± 2.42 mm(3), FU+G₂: 11.42 ± 1.11 mm(3), G₂+FU+GH: 10.47 ± 1.02 mm(3) vs NS: 116.81 ± 10.61 mm(3), P < 0.05. Compared to the GH group, the tumor volumes were significantly decreased in the experimental groups. The GHR protein expression (G₂: 0.39 ± 0.02, FU: 0.40 ± 0.02, FU+G₂: 0.38 ± 0.01, G₂+FU+GH: 0.39 ± 0.01 vs NS: 0.94 ± 0.02, P < 0.05) and the GHR mRNA expression (G₂: 14.12 ± 0.10, FU: 15.15 ± 0.44, FU+G₂: 16.46 ± 0.27, G₂+FU+GH: 15.37 ± 0.57 vs NS: 12.63 ± 0.14, P < 0.05) were significantly decreased and increased, respectively, in the experimental groups.
Inhibition of GHR in human colon cancer SW480 cells resulted in anti-tumor effects in nude mice.
确定 RNAi 介导的生长激素受体(GHR)基因抑制对体内肿瘤和结肠癌细胞的影响。
构建人 GHR 表达的真核载体,pcDNA6.2-GW/EmGFP 小干扰 RNA(siRNAs)-GHR 质粒,用于抑制 GHR 表达。将 36 只 BALB/c 裸鼠随机分为生理盐水(NS)组、重组质粒(G₂)组、生长激素(GH)组、5-氟尿嘧啶(FU)组、FU+G₂ 组、FU+G₂+GH 组。每组裸鼠皮下接种 1×10(7)个人结肠癌 SW480 细胞;接种前和接种后第 2、5、8、11、14 和 17 天称重。接种后第 17 天处死所有裸鼠。切除每个皮下肿瘤并进行研究。在接种后第 5、8、11、14 和 17 天测量肿瘤体积。Western 印迹分析检测肿瘤组织中 GHR 蛋白的表达,实时定量逆转录-聚合酶链反应检测肿瘤组织中 GHR mRNA 表达的差异。
与对照组相比,接种后第 17 天接种裸鼠的体重为:G₂:21.60±0.71 g,GH:21.64±0.45 g,FU:18.94±0.47 g,FU+G₂:19.40±0.60 g,G₂+FU+GH:21.04±0.78 g vs NS:20.68±0.66 g,P<0.05;皮下接种后的肿瘤体积为:G₂:9.71±3.82 mm(3),FU:11.54±2.42 mm(3),FU+G₂:11.42±1.11 mm(3),G₂+FU+GH:10.47±1.02 mm(3) vs NS:116.81±10.61 mm(3),P<0.05。与 GH 组相比,实验组的肿瘤体积明显减小。GHR 蛋白表达(G₂:0.39±0.02,FU:0.40±0.02,FU+G₂:0.38±0.01,G₂+FU+GH:0.39±0.01 vs NS:0.94±0.02,P<0.05)和 GHR mRNA 表达(G₂:14.12±0.10,FU:15.15±0.44,FU+G₂:16.46±0.27,G₂+FU+GH:15.37±0.57 vs NS:12.63±0.14,P<0.05)均显著降低和升高,分别在实验组中。
抑制人结肠癌 SW480 细胞中的 GHR 导致裸鼠抗肿瘤作用。